Author

Sosun Park

Observed name: S.S. Park

Institution: GI Innovation (South Korea)

Observed institution: GI Innovation (South Korea)

OpenAlex ID: A5085854499

A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation.

2024 · Jeeyun Lee, Byoung Chul Cho, et al. · Journal of Clinical Oncology · 4

GI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumour effects in preclinical models

2019 · J.C. Park, K.H. Pyo, et al. · Annals of Oncology · 2

729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors

2023 · Jeeyun Lee, Byoung Chul Cho, et al. · Regular and Young Investigator Award Abstracts

Works count: 3

Citation count: 6

H-index: 2

I10-index: